about
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGNA virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infectionImmunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificityMultivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and miceStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep SequencingOuter Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPsRational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination.Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions.Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining regionReplication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesEbola virus pathogenesis: implications for vaccines and therapies.Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination.Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge.Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus InfectionEfficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsBroadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens.Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virusImmunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccinationImmunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.
P50
Q24563490-43A97ECC-EF3E-42E5-841A-8A439023B088Q24631774-9079FDAB-F2BF-462E-9A4F-6B78457DF4B4Q24646829-88980251-74D3-4EE0-973E-B904A3A1B931Q27301043-720355EE-CD26-4253-ACE7-CB1EFC5E8513Q27644478-372A9D84-C6F2-43E9-BEB8-63146BA43103Q27658449-A229FB76-ABED-42D1-9A8C-2140EC48C362Q27663293-B1176A34-DA1D-4C5E-B39D-EDDF7A4095FBQ27671696-393A4391-1F0A-47B9-8156-F522E838B6A0Q27675468-541B44B5-C924-4788-9F39-3BA93D624284Q27675879-CD2CBA75-E705-4F4A-9CF8-F10642A3506BQ28768041-2F225F78-BB56-41A1-81EB-5DD0B238BDD2Q29619511-15D1AD4E-092C-47E7-81DF-F40ED26B06C4Q30357455-4576821C-B853-4B57-BBA6-B54C8BEE4816Q30387829-B6AECB04-9365-4C7E-930B-F44C829CF861Q30391652-7252F329-0E5B-448A-878B-5D4B14A856EAQ33328766-B3AF6D96-000A-4C35-828B-660462A61A51Q33676600-DD99BB32-460B-433E-9808-94706CB04336Q33780685-FB1A8B36-A54A-4A9E-8E76-CED67C465512Q33967985-8FECC534-A688-48C2-8A2C-0D72CA07A6AEQ34075820-699F071D-A04D-4FBA-A9C9-7D3365625564Q34220503-62FF7CB8-BAC5-4C21-A9FE-7B9A89BC3479Q34355284-DE1AF162-A3F2-4934-AF54-3A88D8361947Q34363707-951C47AB-4232-47C4-B70C-E9325FBE05D9Q34593860-DC268091-AF8B-4EA8-AC3F-D2C479BC2A59Q35123128-C2A792A0-9135-42C8-8556-103D8377BAFAQ35139693-6B79828D-7BB7-472E-A797-D060629BC40FQ35641234-AE0FEE1E-BEAA-44F0-A772-076BF64E39F4Q35677724-D0568BEB-39C9-43DB-B9C9-31930C62EE62Q35914292-9020470E-5877-4926-B04A-FF4573B07987Q36628390-25DD0DD2-1695-409A-AA1A-1B6E6BD3C794Q36638450-B00164D9-22CD-4F10-9DCE-6F34D2029A0CQ36747980-03976355-6BEF-4610-A134-F092EABF5D87Q37059723-A79FDD7B-73F0-4CDC-AC33-153F1470F9FFQ37084521-7135A2FE-A3A5-4CE8-95C3-FB31FE4DB2A8Q37099729-D9AC5761-4C05-4D5F-8ACD-3C24102D82A4Q37625296-F55FC84C-54C9-4844-B00C-4AFFB5746664Q37742938-4578B8FC-2ACE-4EDB-8F02-DC239647F6E1Q40281145-C4307FCB-1BD6-4976-B0B3-6FED4CC127DDQ40433809-D2EF7B7B-80E9-4818-8486-E584AF518D18Q40520942-609EC2A3-A2BA-4CD1-8B9C-FF8FA6AC2E9A
P50
name
Zhi-Yong Yang
@en
type
label
Zhi-Yong Yang
@en
prefLabel
Zhi-Yong Yang
@en